TGFB1 and neoplasm: In preclinical studies, TGF-β inhibitors such as Galunisertib combined with PD-1 reduced the tumor’s immune evasion ability by inhibiting the TGF-β signal and simultaneously activated the T cell-mediated antitumor response [91].